Cationic antimicrobial peptide resistance mechanisms of streptococcal pathogens  by LaRock, Christopher N. & Nizet, Victor
Biochimica et Biophysica Acta 1848 (2015) 3047–3054
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamemReviewCationic antimicrobial peptide resistance mechanisms of
streptococcal pathogens☆Christopher N. LaRock a,⁎, Victor Nizet a,b,c,⁎⁎
a Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA
b Skaggs School of Medicine and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA
c Rady Children's Hospital, San Diego, CA, USA☆ This article is part of a Special Issue entitled: Bacter
Peptides.
⁎ Corresponding author.
⁎⁎ Correspondence to: V. Nizet, Department of Pediatri
Diego, La Jolla, CA, USA.
E-mail addresses: clarock@ucsd.edu (C.N. LaRock), vni
http://dx.doi.org/10.1016/j.bbamem.2015.02.010
0005-2736/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 24 November 2014
Received in revised form 4 February 2015
Accepted 7 February 2015







innate immunityCationic antimicrobial peptides (CAMPs) are critical front line contributors to host defense against invasive
bacterial infection. These immune factors have direct killing activity toward microbes, but many pathogens are
able to resist their effects. Group A Streptococcus, group B Streptococcus and Streptococcus pneumoniae are
among the most common pathogens of humans and display a variety of phenotypic adaptations to resist
CAMPs. Common themes of CAMP resistance mechanisms among the pathogenic streptococci are repulsion,
sequestration, export, and destruction. Each pathogen has a different array of CAMP-resistant mechanisms,
with invasive disease potential reﬂecting the utilization of several mechanisms that may act in synergy. Here
wediscuss recent progress in identifying the sources of CAMP resistance in themedically important Streptococcus
genus. Further study of these mechanisms can contribute to our understanding of streptococcal pathogenesis,
and may provide new therapeutic targets for therapy and disease prevention. This article is part of a Special
Issue entitled: Bacterial Resistance to Antimicrobial Peptides.
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The genus Streptococcus comprises some of the most common, yet
potentially deadly, bacterial pathogens of humans. Medically importantial Resistance to Antimicrobial
cs, University of California, San
zet@ucsd.edu (V. Nizet).streptococcal species are typically carried asymptomatically, but have
signiﬁcant pathogenic potential if not restricted to superﬁcial sites.
Group A Streptococcus (GAS; Streptococcus pyogenes) commonly colo-
nizes themucosal tissues of the nasopharynx or the skin, and is estimat-
ed to cause more than 700 million cases of pharyngitis (“strep throat”)
or superﬁcial skin infections (impetigo) annually worldwide [1]. Less
commonly, GAS is associated with severe invasive infections including
streptococcal toxic shock syndrome and necrotizing fasciitis, and
the pathogen is the trigger of the post-infectious immunologically-
mediated syndromes of rheumatic fever and glomerulonephritis [2].
Group B Streptococcus (GBS; Streptococcus agalactiae) is typically carried
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Upon ascending infection of the placentalmembranes or during passage
through the birth canal, GBS can access the newborn infant, where it is a
major cause of pneumonia, sepsis and meningitis [3]. GBS is also
increasingly associated with invasive infections in adult populations in-
cluding pregnantwomen, the elderly and diabetics [4]. The pneumococ-
cus (Streptococcus pneumoniae), which colonizes the nasal mucosa, is a
major cause of mucosal infections such as otitis media and sinusitis, as
well as pneumonia, sepsis in meningitis, especially at the ends of the
age spectrum and throughout the developing world [5,6]. Streptococcus
mutans colonizes the mouth, where it is a major contributor to tooth
decay. Additional Streptococcus spp., more rarely associated with disease
in humans, are pathogenic for other animal species, e.g. Streptococcus
suis (swine) and Streptococcus iniae (ﬁsh).
A critical ﬁrst line of host innate defense against invasive infections
by pathogenic streptococci is provided by endogenous cationic antimi-
crobial peptides (CAMPs). CAMPS are produced by epithelial cells and
by circulating immune cells including neutrophils and macrophages,
and are among the ﬁrst immune effectors encountered by an invading
microbe [7,8]. CAMP expression is greatly induced during infection; it
is also induced in sterilemodels of injury that compromise the epithelial
barrier, indicating that it can function as a prophylactic measure against
imminent pathogen invasion [9].
Two major classes of the CAMPs present in mammals are the
cathelicidins and the defensins (Fig. 1). Both represent small, cyto-
toxic pore-forming peptides that contain regions of strong cationic
charge that intersperse solvent-exposed hydrophobic residues. ThisFig. 1. Common electrostatic properties of antimicrobial peptides. Themature fragment of
human cathelicidin, LL-37, is an α-helical peptide (pdb: 2K6O), while the defensins can
have a number of different folds (pdb: 1FD3, 1E4S, 2PM1). These peptides have in com-
mon a strongly cationic face that mediates the electrostatic attraction to the cell surface
of the Streptococci and other microbes.amphiphilicity is a key source of their antimicrobial activity; the posi-
tive charge attracts them to a microbe's surface and their hydrophobic
surfaces insert into and permeabilize the bacterial membrane. An
additional target of CAMPs is the ExPortal, an organelle dedicated to
the biogenesis of secreted proteins in streptococci and entercocci [10].
Since many of the CAMP resistance mechanisms that will be discussed
rely on the secretion of proteins through this system, thismay represent
a way to counter these resistance mechanisms. In addition to directly
targeting the pathogen, CAMPs can also coordinate the immune re-
sponse to infection by contributing to cytokine signaling, immune cell
chemotaxis, and wound healing [11–13]. Therefore, some microbial
mechanisms for counteract CAMPs can also impact these downstream
immune pathways.
Defensins are highly polymorphic, with numerous alleles expressed
by various immune cell types. In contrast, mice and humans express only
one cathelicidin: hCAMP18 (human) or mCRAMP (murine). These
proteins aremade of a conserved amino-terminal cathelin (protease in-
hibitor) domain and a highly charged alpha-helical carboxy-terminus.
Cathelicidins are not antimicrobial until the cathelin pro-domain is pro-
teolytically removed, freeing the remaining peptide, in humans named
LL-37, to act against the microbe [14]. In addition to these classical
CAMPs, cathelicidins and defensins, several other proteins and their
degradation products are cationic and antimicrobial. These proteins
include lysozyme, histones, thrombocidin, lactoferrin, cathepsins,
myeloperoxidase, kininogen, and heparin-binding proteins. Many of
these proteins are found in neutrophil extracellular traps (NETs),
web-like structures in which these cationic antimicrobials are embed-
ded within an extruded (acidic) DNA matrix [15]. NETs can potentiate
killing of extracellular microbes, which will be trapped and exposed to
a higher local concentration of cathelicidin and other CAMPs. While
neutrophils are critical in controlling streptococcal infections, additional
cells make NET-like structures that may also function in pathogen
defense [16].
While mechanisms of resistance to cathelicidin/LL-37 or defensins
do not always correlate with one another [17], many of the virulence
factors the pathogens employ to evade one CAMP can be cross protec-
tive against others. Nearly any virulence factor of a pathogen may con-
tribute, at least indirectly, to a pathogen's resistance or susceptibility
to CAMPs. For example, pore-forming toxins induce cell death that can
eliminate CAMP-producing cells [18], secreted DNases can facilitate es-
cape fromNETs [19], and any number of mechanisms that shield poten-
tial pathogen-associated molecular patterns can work to lessen the
induction of CAMP expression via TLRs [20]. In this review,we focus pri-
marily on molecular mechanisms that directly target CAMPs, by the
common themes of repulsion, sequestration, export, and destruction
(Fig. 2). We further discuss how streptococcal pathogens detect and
regulate their gene expression to resist these CAMPs, and emerging
strategies toward combatting infection by boosting or supplementing
CAMP defenses.
2. Repel
One of the ﬁrst mechanisms recognized by which pathogens evade
killing by CAMPs is directed at one of their rudimentary properties —
charge. The outer leaﬂet of the mammalian cell contains zwitterionic
phospholipids and carries little negative charge that would attract
CAMPs, which protect cells from toxicity from these molecules. CAMPs
are attracted to bacterial membranes, which are abundant in acidic
phospholipids. Streptococci, like other Gram-positive bacteria, are addi-
tionally coatedwith an acidic polymer of teichoic acids on their cellwell.
When a bacterium can increase its net surface charge to more closely
resemble the charge proﬁle of a mammalian cell, it can decrease the
afﬁnity of cationic molecules like CAMPs to its surface. This can be ac-
complished by several chemical modiﬁcations possible for each layer
of the cell surface: the lipid membrane, the peptidoglycan and teichoic
acid-containing cell wall, and the capsular polysaccharides.
Fig. 2. Models of streptococcal resistance to cationic antimicrobial peptides. CAMPs
attracted to the cell surface form pores that disrupt membrane integrity (Killing). Patho-
gens, including the streptococci, are able to detect CAMPs either directly or indirectly via
sensors. Detection of sub-inhibitory concentrations of CAMPs can induce resistancemech-
anisms protective for when higher CAMP concentrations are encountered (Response). Ex-
amples of these resistance mechanisms are cell surface modiﬁcation (Repel), competitive
binding (Intercept), removal or secretion (Efﬂux), or proteolytic inactivation (Destroy).
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their lipid cell membrane in a manner providing resistance to CAMPs.
Several Gram-positive pathogens have been reported to modify the
acidic membrane lipid phosphatidylglycerol with the cationic amino
acid, L-lysine [21], reducing the net negative charge of the membrane,
thereby decreasing attraction of CAMPs. This L-lysinylation reaction is
carried out by a lysyl-phosphatidylglycerol synthase encoded bymprF,
a gene absent from the GAS and pneumococcal genomes. GBS do pos-
sessmprF, but deletion of the gene did not signiﬁcantly alter resistance
to CAMPs [22]. The mprF gene is present in the sequenced genomes of
other veterinary/zoonotic pathogens including S. iniae and S. suis, but
any contribution to CAMP resistance has yet to be demonstrated.
The Gram-positive cell membrane is covered by the cell wall, a rigid
porous mesh composed of heavily cross-linked peptidoglycan. The
backbone of peptidoglycan consists of N-acetylglucosamine and N-
acetylmuramic acid linked by short peptides. Two modiﬁcations that
streptococci can make to this base structure are N-deacetylation of the
N-acetylglucosamine subunit, carried out by PgdA, and O-acetylation
of the N-acetylmuramic acid, catalyzed by OatA (Adr). Despite increas-
ing surface charge and lysosome resistance, N-deacetylation does not
alter CAMP resistance in S. pneumoniae [23] nor S. suis [24]. O-acetyla-
tion also increases surface charge and decreases binding of cationic pro-
teins. However, for S. iniae this did not translate to altered CAMP
susceptibility [25]. In S. pneumonia, O-acetylation does increase resis-
tance to lysosome, which is cationic [26], but the effect on CAMP resis-
tance was not evaluated. The same N-deacetylation and O-acetylation
mechanisms confer CAMP resistance in other species, suggesting that
they may still act in streptococci in manners yet to be evaluated.
Teichoic acids make up a second major component of the Gram-
positive cell wall. These glycerophosphate polymers are anchored to
the peptidoglycan and cell membrane, and like both, are also acidic.
The dlt operon encodes enzymes mediating D-alanylation of wall
teichoic acids, a modiﬁcation nearly ubiquitous among Gram-positive
pathogens. The highly cationic side chain of alanine increases cell sur-
face charge; cell wall density is concurrently increased by a mechanismthat is not yet entirely clear [22]. Together, these changes increase resis-
tance to CAMPs, as well as bacteriocins, lysozyme, acid, and NETs, and
thereby the major immune cells producing these antimicrobial factors,
neutrophils [27–29]. Thus, dlt is important for the virulence of GAS
[29], GBS [30], S. pneumoniae [27], S. suis [31], and S. mutans [32]. The
conservation of the phenotype of dlt mutants between these species
clearly illustrates its advantageous role in direct resistance to CAMPs,
however, some care must be taken to avoid over interpreting results
from mutations like this that alter fundamental cell structures. For ex-
ample, the increased CAMP susceptibility of GAS dlt mutants may not
be solely a consequence of failing to modify cell techoic acids, but also
due to lower expression levels of M protein and SIC [33], two important
virulence factors that also contribute to CAMP resistance in this species
[34,35].
The third component of the streptococcal cell wall is the Lanceﬁeld
group-speciﬁc carbohydrate. These carbohydrates compose up to half
the cell wall by weight, and provide the basis for the serological separa-
tion of streptococcal groups. In groups A and C streptococci, the antigen
consists of a polyrhamnose backbone and immunodominant side-chain
speciﬁc to each group. The functional role of these carbohydrates had
long remained a mystery, but recently, it was shown that the group A
carbohydrate of GAS has an N-acetylglucosamine side-chain which
blocks LL-37 binding, thereby providing resistance to CAMPs as well
as killing by neutrophils and NETs [36].
Another method to repel CAMPs is the recruitment of factors to in-
crease thenet charge of the bacteria surface, rather than to directlymod-
ify it. An example of this mechanism can be found in S. pneumoniae
where the LytA protein decorates the bacterial surface with highly
charged choline [37]. This masking could decrease attraction of CAMPs,
as in the respiratory pathogen Haemophilus inﬂuenzae, recruitment of
choline to its surface, albeit by a differentmechanism, does afford signif-
icant protection against CAMPs [38]. Separate fromproviding protection
from CAMPs, pneumococcal cholate binding does contribute NET resis-
tance [28]. Lipoteichoic acid D-alanylation did not affect NET trapping
of pneumococci, but did provide the pathogen protection against killing
by CAMPs embedded within the NET [28].
The most distal surface on many Gram-positive bacteria is an
exopolysaccharide capsule. This family of critical virulence factors
shields the bacterial surface and promotes resistance to phagocytosis
and complement [39]. This alsomasks susceptible underlying cell layers
from CAMP action, as GAS lacking their hyaluronic acid capsule is more
susceptible to CAMPs, neutrophils, and NETs [40]. Mutations altering
capsule can similarly sensitize S. iniae [41] and S. pneumoniae [42] to kill-
ing by CAMPs. Interestingly, capsule expression can instead sensitize a
bacterium to killing by some CAMPs; as some strains of encapsulated
S. pneumoniae are more sensitive to defensins [43], possibly a result of
increased attraction of CAMPs to the bacterium by a particularly anionic
capsule composition. Yet, during infection this interaction could also
translate into a virulence mechanism; several pathogens including
S. pneumoniae dynamically shed their negatively charged capsular poly-
saccharide in vivo, which can intervene and neutralize CAMPs before
they can bind the underlying cell structures [42]. This mechanism of
binding CAMPs before they can ﬁnd their cellular target introduces the
second method of protection against CAMPs; interception.
3. Intercept
Streptococci decorate their outer surface with numerous proteins
that inhibit immune functions ranging from phagocytosis to cytokine
signaling. Some of these proteins encode for more than one activity,
and one of the common accessory functions of these proteins is provid-
ing CAMP resistance. One of the earliest of these identiﬁed proteins is
the serum inhibitor of complement (SIC), ﬁrst characterized for its
role in protection against killing by the membrane attack complex
[44], but later found to also bind and inhibit killing by defensins and
LL-37 [45]. Consequently, SIC is required for the full virulence of GAS
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ing another GAS protein, distantly related to SIC (DRS) [46], and the
Streptococcus dysgalactiae subsp. equisimilis (GCS/GGS) protein DrsG
[47].
One of the major surface proteins of GAS is the ﬁmbrial M protein.
This immunodominant surface anchored protein is multifunctional
during infection, and can varyingly promote or inhibit adhesion and
invasion of mammalian cells, inhibit complement and opsonization,
induce inﬂammation, and act as a superantigen [48]. These broad activ-
ities are not universal among isolates, due to both a varying modular
arrangement of domains and a region of hyper-variability, which serves
as the basis for the serological classiﬁcation of isolates from this species.
OneMprotein variant encoded by the isolatesmost commonly associat-
ed with infection, M1, can directly bind CAMPs like LL-37 andmCRAMP
[34]. This sequestration can signiﬁcantly increase the resistance of M1
GAS Strains to CAMPs, and such isolates with higher CAMP resistance
are more commonly associated with severe disease [34]. Another
common M-type, M49, did not bind CAMPs, but since more than one
hundredM-types have been identiﬁed, but it is not yet clear howperva-
sive M-mediated CAMP resistance might be among GAS.
Another major cell surface structure provides CAMP resistance for
GBS through an interception mechanism: the pilus. GBS pili have been
primarily characterized for their role in adhesion, but the major pilin
subunit of this complex, PilB, can also sequester CAMPs like LL-37 and
mCRAMP, [49]. As with M protein and SIC, the surface charge of the
bacteria is not appreciably altered by the presence or absence of thepro-
tein. Also likeM protein and SIC, inhibition of CAMPs seems to be highly
variable and not all isolates of GAS and GBS make pilin, and not all pilin
have this activity [50]. The GBS penicillin binding protein PBP1a also
likely acts through competitive binding [51]. PBPs are surface localized
and often important for cell well biosynthesis, butmany have unknown
or unrelated cellular roles. PBP1a itself is not necessary for critical cellu-
lar pathways such as cellwall biosynthesis, as amutant can bemade and
is fully viable, but has a virulence defect in vivo [52]. This attenuation
may be largely due to a vulnerability to CAMPs, since a PBP1a mutant
is more sensitive to killing by LL-37, CRAMP, and defensin [51]. Since
all of these proteins have other clear virulence functions, CAMP resis-
tance might be considered to be more of an accessory function second-
ary to their other contributions to the cell, similar to many members of
the next category of CAMP resistance factors, those that affect export.
4. Export
Efﬂux pumps are an important contributor to virulence in several
Gram-positive pathogens. However, efﬂux pumps that provide resis-
tance to CAMPs have most extensively been studied in Gram-negative
pathogens [53]. S. pneumoniae encodes an efﬂux pump for macrolides,
MefE, that also provides protection against defensins, LL-37, and
CRAMP [54]. This cross-protection would suggest that many such efﬂux
pumpsmight provide resistance, and S. pneumoniae encodes several ad-
ditional possible transporters [55]. Mutation of some of these putative
transporters increases pneumococcal CAMP susceptibility, suggesting
they are expressed and active [56]. The homolog of one of these,
SP0912–0913 (MbrCD) has also been found in S. mutans to contribute
to resistance against defensins [57]. While not well studied in other
streptococci, many of these genes are found in additional species; if
they are conﬁrmed to act as CAMP efﬂux pumps, this could represent
signiﬁcant contributor to CAMP resistance throughout the genus
Streptococcus.
5. Destroy
One last, very direct, mechanism for resisting killing by CAMPs is to
destroy them. This can be accomplished by secreted proteases that
hydrolyze the peptides before they can exert their cytotoxic activities.
Gram-positive pathogens, in particular, are proliﬁc secretors of proteasesthat target host proteins. The factors can promote virulence by
inactivating antibodies, cytokines, complement proteins, autophagy
machinery, and many other immune factors, including CAMPs. Howev-
er, targeting of CAMPs is not a universal property of even highly active
bacterial proteases, suggesting that these molecules are not generally
protease-sensitive; the virulence factor needs to speciﬁcally target the
CAMP. For instance, even though the IgG protease of GAS, Mac/IdeS, is
very highly expressed, it provides no resistance to LL-37 [58].
However, GAS does secrete at least one protease active against
CAMPs: SpeB. This intensively studied cysteine protease has been
found to cleave numerous host proteins in both extracellular and intra-
cellular locations [59,60] including the CAMPs LL-37 [61] and β-
defensin [62]. In addition to directly hydrolyzing CAMPs into inactive
or less active forms, SpeB can target other factors in ways that interfere
with killing. SpeB degradation of tissue proteoglycans releases glycos-
aminoglycans like dermatan sulfate, a charged molecule which can
bind and inhibit CAMPs including α-defensin [63] and LL-37 [64].
SpeB-mediated CAMP protection can be ampliﬁed even further
through the activity of a second GAS virulence factor, G-related α2-
macroglobulin-binding protein (GRAB) [65]. This surface protein
forms a complex with the circulating α2-macroglobulin, an abundant
broad-spectrum protease inhibitor with numerous roles in maintaining
homeostasis. Proteases trapped by α2-macroglobulin lose the ability to
process large substrates, however, peptides small enough to penetrate
the α2-macroglobulin:GRAB:SpeB complex are still cleaved [65]. Thus,
this complex can both retain SpeB on the bacterial surface where it
can be most efﬁcacious against CAMPs, while also maintaining the pro-
teolytic activity of SpeB, and possibly even amplifying it by antagonizing
hydrolysis of other possible substrates of SpeB.
Instead of producing its own proteases, a bacterial pathogen can also
recruit and utilize host proteases. The virulence factor streptokinase
(Ska) allows GAS to recruit and activate host plasminogen on the bacte-
rial surface [66]. Recruitment of plasminogen is relatively common
strategy of pathogens; plasminogen is the precursor zymogen of plas-
min, a serine protease that degrades ﬁbrin clots, connective tissue, and
extracellular matrix. Plasmin activated by streptokinase can contribute
to the virulence of GAS by dissolving ﬁbrin deposits to promote dissem-
ination throughout a host tissue [66]. In addition to this activity
targeting the host ﬁbrinolytic system, plasmin activated by streptoki-
nase is able to cleave the cathelicidins LL-37 and CRAMP, which
increases the bacterium's resistance to these CAMPs [67].
The role of proteases in providing CAMP resistance to other strepto-
coccal species is not yet fully clear. Other important human pathogens
including Staphylococcus aureus, Pseudomonas aeruginosa, and
Porphyromonas gingivalis all make proteases that target CAMPs [61].
Therefore, even though obvious homologs of SpeB are not found in
the other pathogenic streptococci, a common activity from dissimilar
and unrelated proteases suggest that other proteases may have a
CAMP neutralizing function. Obvious candidates would be proteases
that are highly expressed and are secreted. For GBS, this would include
ScpB and CspA, and for S. pneumoniae, the serine protease PrtA. In addi-
tion to making their own CAMP proteases, streptococci other than GAS
may utilize streptokinase-activated plasmin for this purpose; GBS, GCS,
and pneumococcus can all activate plasminogen [68].
One caveat for a pathogen resisting CAMPs through proteolysis is the
possibility of working at cross-purposes and inactivating other impor-
tant virulence factors. In addition to cleaving CAMPs, SpeB also degrades
streptokinase, M1 protein, and host plasminogen; consequently, SpeB
can be a barrier to invasive disease [69]. These proteins all contribute
to CAMP resistance, thus providing a very clear example of the shared
beneﬁts and liabilities of SpeB expression. Since it is highly expressed
in vivo and maintained within the GAS pan-genome, the virulence
tradeoff to SpeB is context-dependent. Nonetheless, SpeB is be observed
to colocalize with LL-37 in tissue samples from patients with invasive
GAS infection, suggesting that it may remain a dominant virulence
factor for the degradation of CAMPs [70].
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is the possibility of crosstalkwith their activatingproteases. As anexam-
ple, cathelicidin is synthesized as a propeptide and requires protease
cleavage to release the antimicrobial carboxy-terminus (LL-37 and
related peptides). Cleavage of a CAMP by a microbial protease in the
wrong site could end up liberating a CAMP, rather than destroying
one. Furthermore, the remaining amino-terminal cathelin domain of
cathelicidin has homology with the cystatin family of cysteine protease
inhibitors [14]. Since this will be present in the same tissue as the active
CAMP, it could inhibit microbial attempts to destroy CAMPs. Additional-
ly, protease inhibitors in general are some of themost common circulat-
ing proteins. In an infection context, the presence of inhibitors that can
target bacterial proteases could dampen the ability of bacteria to
destroy CAMPs, despite experiments that readily observe hydrolysis of
CAMPs in vitro [9].
6. Regulation
The ability of a microbe to respond to environmental stimuli and
stressors can allow expression of costly or conditionally detrimental
proteins in only the contexts that are beneﬁcial for the microbe.
Response regulators sensitive to CAMPs that allow a pathogen to selec-
tively induce any of the resistance mechanisms mentioned above could
greatly increase the adaptability and virulence potential. The archetype
of this response is the PhoPQ two-component regulatory system of
Salmonella. The sensor PhoQ contains an acidic patch that binds CAMPs,
subsequently signaling through PhoP to induce CAMP-protective cell
surface modiﬁcations [71]. It is unknown whether pathogenic strepto-
cocci encode sensors that directly recognize CAMPs, but several
response regulator components are responsive to CAMPs.
The GAS CovRS (CsrRS) two-component system is the most charac-
terized of these response regulators. CovRS-regulated genes are activat-
ed by the CAMP LL-37 and repressed by high Mg2+ [72], similar to the
PhoPQ paradigm where CAMP activates and Mg2+ represses gene ex-
pression [71]. CovS is the sensor of this pair, and CovR a transcriptional
repressor that is inactivated by CovS signaling [73]. Mutation of CovR
and CovS, singly or in combination, appears to onlymodestly alter resis-
tance of GAS to the CAMP LL-37, a difference that was signiﬁcant in one
study [74] but not another [75]. Nonetheless, virulence factor induction
through LL-37 dependent CovRS signaling is protective during infection,
indicating that it may be more potent at counteracting other immune
mechanisms [72,76]. Clear homologs of CovRS are present in other
streptococci including GBS where it shares the same name; their role
in the detection of and resistance to CAMPs is not yet clear, but these
two-component systems similarly regulate virulence factor expression
and impact pathogenesis [77].
Which CovRS-regulated proteins contribute to CAMP resistance is
not fully clear; 10% of the entire GAS genome is differentially regulated
by CovRS [78]. Many CovRS-regulated genes encode virulence factors,
including several known to provide resistance to CAMPs. SpeB expres-
sion is abolished in a CovRS mutant, while SIC and the operon encoding
hyaluronic acid capsule biosynthesis (has) are more highly expressed.
The counterbalance of these CAMP resistance mechanisms might
explain why CovRS mutants are not more highly sensitive to CAMPs
than mutants for any particular resistance factors, like M1, SIC, capsule,
or SpeB. This interplay is further complicated by SpeB degradation of
other CAMP resistance factors, counterbalanced by the naturally occur-
ring CovS mutants that arise during invasive infection [79].
CovRS is active in GBS, but it is unknown whether it is also respon-
sive to CAMPs. However, GBS do induce several known and putative
CAMP resistance factors in response to sub-inhibitory concentrations
of LL-37 [56]. Two different two-component system response regulators
are known to be involved: LiaR [80] and CiaR [81]. Both systems induce
resistance to CAMPs like LL-37 and CRAMP, but it is not knownwhether
the sensor kinases of the systems, LiaS and CiaS, directly detect the
CAMPs or whether they transduce signals downstream of some effectthat CAMPs have on the cell or its environment. LiaR-mutant bacteria
are less piliated, express less of the penicillin-binding protein PbP2b,
and less peptidoglycan cross-linking enzymes, which could all relate
to this CAMP susceptibility [80]. LiaRS is also active in S. pneumoniae
and S. mutans; it is not known whether it mediates CAMP resistance in
these species, but it shows sensitivity to many of the same stressors as
the GBS system [82,83]. Genes regulated by CiaR are more cryptic in
function, but include several proteases, which might be responsible
for increased CAMP resistance if they were capable of degrading the
molecules. However, CiaR also regulates resistance to stresses like hy-
drogen peroxide and hypochlorite, which could suggest a more broad
regulation of protective modiﬁcations of the cell surface. Another regu-
lator of GAS, CrgR, strongly increases resistance of GAS to the murine
CRAMP [84]. While the factors mediating this resistance are not
known, this mutant only outcompetes wild-type GAS in the presence
of CRAMP and during infection CRAMP knockout mice, indicating that
the CrgR virulence phenotype is highly speciﬁc to CAMP resistance.
Several regulators important for CAMP resistance in other species
are present in the pathogenic streptococci but their contribution to vir-
ulence is not yet fully characterized. Staphylococcus epidermidis uses
ApsXRS to induce the dlt operon and MprF in response to defensin
and LL-37 [85]. dlt and MprF also contribute to CAMP resistance in
many streptococcal species, and clear homologs to the Aps system are
present in some of the strains. Similarly, the BceRS (MbrAB) bacitracin
sensor and response regulator can detect and initiate a protective re-
sponse against CAMPs for Bacillus subtilis [86]. This system is found in
several streptococcal pathogens. BceRS has been studied in S. mutans
where it was still found to work against bacitracin, but no cross-
protection against other CAMPs was found [57]. The CpsY (MetR/
MtaR) regulator of S. iniae modulates expression of genes involved in
peptidoglycan acetylation [25]. Mutation of CpsY led to an increase in
surface charge and susceptibility to lysozyme, though no difference in
LL-37 killingwas observed [25]. Since decreased surface charge general-
ly inhibits CAMP attraction, this could still mediate resistance to other
CAMPs, especially if a CpsY inducer were uncovered that could lead to
greater induction of this pathway.
7. Conclusion
The pathogenic streptococci employ a large, often redundant, array
of CAMP resistance mechanisms (Table 1). While highlighting a persis-
tent evolutionary selective pressure to escape CAMP killing, it is telling
that streptococci have not found a complete solution; the high CAMP
concentrations and diverse CAMP repertoire that are detected in vivo
[87] still restrict streptococci employing their full complement of resis-
tance mechanisms in the vast majority of host–pathogen encounters.
Since CAMPs are ancient molecules present in all forms of life and
remain critical in the human immune system, high level-resistance, as
seen for most modern pharmaceutical antibiotics, just might not be
achievable for a bacterium. This recognition suggests that enhancing
endogenous CAMP function could provide an attractive avenue for the
treatment of bacterial infections.
Low levels of defensin and LL-37 correlatewith atopic dermatitis and
susceptibility to bacterial infection [87]. Mice deﬁcient in the
cathelicidin CRAMP are hyper-susceptible to GAS infection [84], while
transgenicmice expressing additional CAMP aremore resistant to infec-
tion [88,89]. Therefore, boosting the expression of endogenous CAMPs
might be seen to have both prophylactic and therapeutic potentials in
combating streptococcal infection. Vitamin D receptor signaling induces
expression of human cathelicidin, camp, and β-defensin, defB2, but not
the murine cramp [90,91]. This pathway can be further ampliﬁed by
TLR signaling in response to pathogen-associated molecular patterns
[20] or during injury, likely in response to damage-associatedmolecular
patterns [92]. Similarly, infection can induce HIF, a global regulator in
response to hypoxia that is important for CRAMP expression [93–95].
HIF can also be boosted pharmacologically, boosting cathelicidin
Table 1
Summary of the CAMP resistance mechanisms of streptococcal pathogens. GAS, group
A Streptococcus; GBS, group B Streptococcus; GCS, Group C (and G) Streptococcus; SPN,
Streptococcus pneumoniae; Sm, Streptococcus mutans; and Ss, Streptococcus suis.
Category Speciﬁc mechanism References
Repel
DltABC Lipotechoic acid D-alanylation GAS [29], GBS [30], SPN [27],
Ss [31], Sm [32]





M1 Competitive binding GAS [34]
SIC/DRS Competitive binding GAS [45], [46], GCS [47]
Scl-1 Competitive binding GAS [97]
PilB Competitive binding GBS [49]
PBP1a Competitive binding GBS [51]
Dermatan
sulfate
Competitive binding by host




SP0785-7 ABC transporter (putative) Sp [56]
MbrCD ABC transporter (putative) Sm [57], Sp [56]
MefE Efﬂux pump Sp [54]
Destroy
SpeB Direct proteolysis GAS [61]
GRAB Protease recruitment/redirection GAS [65]
Ska Activation of proteolysis by plasmin GAS [67]
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of invasive streptococcal infections [96].
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